186 related articles for article (PubMed ID: 35649187)
1. Paraneoplastic syndromes in hepatocellular carcinoma: a review.
Ong Y; Huey CWT; Shelat VG
Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):449-471. PubMed ID: 35649187
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic syndrome frequency and prognostic effect in hepatocellular carcinoma patients.
Ülger Y; Delik A
Eur J Gastroenterol Hepatol; 2022 Jul; 34(7):769-773. PubMed ID: 34974464
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
Burciu C; Sirli R; Bende R; Vuletici D; Miutescu B; Moga T; Bende F; Popescu A; Sporea I; Koppandi O; Miutescu E; Iovanescu D; Danila M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674198
[No Abstract] [Full Text] [Related]
4. Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma.
Qu Q; Wang S; Chen S; Zhou L; Rui JA
Am Surg; 2014 Feb; 80(2):191-6. PubMed ID: 24480222
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma.
Chang PE; Ong WC; Lui HF; Tan CK
ISRN Oncol; 2013; 2013():684026. PubMed ID: 24396608
[TBL] [Abstract][Full Text] [Related]
6. [The incidence and clinical significance of paraneoplastic syndromes in patients with hepatocellular carcinoma].
Huh UY; Kim JH; Kim BH; Nam KD; Jang JY; Kim NH; Lee SK; Joo KR; Dong SH; Kim HJ; Chang YW; Lee JI; Chang R
Korean J Hepatol; 2005 Sep; 11(3):275-83. PubMed ID: 16177554
[TBL] [Abstract][Full Text] [Related]
7. Manifestations of hypercholesterolaemia, hypoglycaemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases.
Chu CW; Hwang SJ; Luo JC; Tsay SH; Li CP; Chang FY; Lee SD; Lui WY; Chiang JH
J Gastroenterol Hepatol; 1999 Aug; 14(8):807-10. PubMed ID: 10482434
[TBL] [Abstract][Full Text] [Related]
8. [A case of hepatocellular carcinoma with paraneoplastic hypercholesterolemia, thrombocytosis and hypoglycemia].
Inomata E; Sohda T; Nakane H; Morihara D; Hirose O; Kitamura Y; Iwata K; Irie M; Takeyama Y; Watanabe H; Sakisaka S
Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1231-5. PubMed ID: 17675826
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes.
Luo JC; Hwang SJ; Wu JC; Lai CR; Li CP; Chang FY; Chiang JH; Lui WY; Chu CW; Lee SD
Hepatogastroenterology; 2002; 49(47):1315-9. PubMed ID: 12239934
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.
Lemekhova A; Hornuss D; Polychronidis G; Mayer P; Rupp C; Longerich T; Weiss KH; Büchler M; Mehrabi A; Hoffmann K
World J Surg Oncol; 2020 May; 18(1):93. PubMed ID: 32397993
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization for palliation of paraneoplastic hypoglycemia in a patient with advanced hepatocellular carcinoma.
Whitsett M; Lindenmeyer CC; Shaw CM; Civan JM; Fenkel JM
J Vasc Interv Radiol; 2013 Dec; 24(12):1918-20. PubMed ID: 24267531
[No Abstract] [Full Text] [Related]
12. Thrombocytosis as a Rare Paraneoplastic Syndrome Occurring in Hepatocellular Carcinoma: A Case Report.
Abbas H; Hanif S; Tariq H; Chilimuri S
Gastroenterology Res; 2019 Apr; 12(2):96-99. PubMed ID: 31019620
[TBL] [Abstract][Full Text] [Related]
13. Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib.
Apostolidis L; Kahlert C; Siegmund A; Thom R; Horstmann S; Jäger D; Lordick F
Onkologie; 2009 Feb; 32(1-2):50-3. PubMed ID: 19209021
[TBL] [Abstract][Full Text] [Related]
14. A case of hepatocellular carcinoma associated with troublesome hypoglycemia: management by cytoreduction using percutaneous ethanol injection.
Saigal S; Nandeesh HP; Malhotra V; Sarin SK
Am J Gastroenterol; 1998 Aug; 93(8):1380-1. PubMed ID: 9707076
[TBL] [Abstract][Full Text] [Related]
15. Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma.
Hegemann M; Kroeger N; Stenzl A; Bedke J
World J Urol; 2018 Jun; 36(6):849-854. PubMed ID: 29429069
[TBL] [Abstract][Full Text] [Related]
16. Mistakes in managing hepatocellular carcinoma and how to avoid them: a narrative review.
Niriella MA; Dassanayake U; de Silva HJ
Expert Rev Gastroenterol Hepatol; 2023; 17(9):913-919. PubMed ID: 37671550
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic syndromes in patients with oral cancer.
Toro C; Rinaldo A; Silver CE; Politi M; Ferlito A
Oral Oncol; 2010 Jan; 46(1):14-8. PubMed ID: 19932048
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan.
Luo JC; Hwang SJ; Wu JC; Li CP; Hsiao LT; Lai CR; Chiang JH; Lui WY; Chang FY; Lee SD
Cancer; 1999 Sep; 86(5):799-804. PubMed ID: 10463978
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic syndromes in primary liver cell carcinoma in Nigeria.
Teniola SO; Ogunleye IO
Trop Geogr Med; 1994; 46(1):20-2. PubMed ID: 8165731
[TBL] [Abstract][Full Text] [Related]
20. A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients.
Abdelaziz AO; Shousha HI; Abdelmaksoud AH; Saad Y; Elbaz TM; Soliman ZA; Salah A; Lithy R; Ahmed M; Nabil MM
Eur J Gastroenterol Hepatol; 2018 May; 30(5):514-519. PubMed ID: 29465472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
